オピオイド誘発性便秘治療の世界市場レポート 2025年

オピオイド誘発性便秘治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で24億7,000万米ドルに成長します。予測期間の成長は、医薬品承認への取り組みの加速、オピオイド鎮痛薬の処方増加、新規治療法の研究開発費の急増、生物学的製剤の開発増加などに起因しています。予測期間における主な動向としては、患者の教育と意識向上、標的療法の出現、非薬理学的介入、バイオテクノロジーの革新、投資の増加などが挙げられます。

がんおよびがん以外の疼痛管理のためにオピオイドの使用が増加していることが、今後のオピオイド誘発性便秘（OIC）治療市場の成長を牽引すると予想されます。がん性疼痛とは、がんおよびその治療に伴う痛みを指し、非がん性疼痛はがんとは無関係の症状から生じる。このような疼痛に対するオピオイドの投与は、中等度から重度の疼痛を効果的に管理する必要性によって推進されており、疼痛の強度、持続時間、他の治療に対する患者の反応などの要因を考慮し、中毒や副作用のリスクを最小限に抑えながらQOLを改善することを目標としています。OIC治療は、オピオイド使用による便秘を緩和し、疼痛緩和を犠牲にすることなく、患者の快適性、疼痛管理レジメンへのアドヒアランス、全体的なQOLを改善します。例えば、カナダ政府によると、2025年までに最大830万人のカナダ人が慢性疼痛を経験し、この数は2030年までに900万人に増加すると予測されています。その結果、がんや非がん性疼痛の管理にオピオイドが使用されるようになり、OIC治療市場の拡大に寄与しています。

オピオイド誘発性便秘（OIC）治療市場の主要企業は、革新的な医薬品を開発するために戦略的パートナーシップを採用するようになってきています。このような提携により、OIC治療薬企業はリソースや専門知識を共有し、研究開発能力を強化し、市場でのプレゼンスを拡大し、新製品の商業化を加速することが可能となり、業界の革新と成長を促進しています。例えば、2022年11月、日本のバイオテクノロジー企業である協和発酵キリン株式会社は、OIC治療薬の共同開発を開始しました。日本を拠点とするバイオテクノロジー企業である協和キリン株式会社は、ドイツを拠点とする製薬企業であるGrunenthal GmbHとパートナーシップを締結しました。この提携は、オピオイド誘発性便秘、画期的ながん性疼痛、骨粗鬆症の治療を含む、革新的な疼痛管理薬のポートフォリオの成長と世界の利用可能性の拡大を目指し、それによって世界的に患者の転帰を改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オピオイド誘発性便秘治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のオピオイド誘発性便秘治療市場：成長率分析
• 世界のオピオイド誘発性便秘治療市場の実績：規模と成長, 2019-2024
• 世界のオピオイド誘発性便秘治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界オピオイド誘発性便秘治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオピオイド誘発性便秘治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下剤
• 末梢作用型μオピオイド受容体拮抗薬
• セロトニン受容体作動薬
• プロスタグランジン
• 世界のオピオイド誘発性便秘治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界のオピオイド誘発性便秘治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のオピオイド誘発性便秘治療市場下剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 浸透圧性下剤
• 刺激性下剤
• 膨張性下剤
• 世界のオピオイド誘発性便秘治療市場末梢作用型オピオイド受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナロキセゴール
• メチルナルトレキソン
• アルビモパン
• 世界のオピオイド誘発性便秘治療市場セロトニン受容体作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プルカロプリド
• テガセロド
• 世界のオピオイド誘発性便秘治療市場プロスタグランジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ルビプロストン

第7章 地域別・国別分析

• 世界のオピオイド誘発性便秘治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオピオイド誘発性便秘治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オピオイド誘発性便秘治療市場：競合情勢
• オピオイド誘発性便秘治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Chemical Pharma Co. Ltd.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH.
• Shionogi & Co. Ltd.
• Ono Pharmaceutical Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Mundipharma International Limited
• Lantheus Holdings Inc.
• Indivior plc
• Mallinckrodt Pharmaceuticals
• Collegium Pharmaceutical Inc.
• Ironwood Pharmaceuticals Inc.
• Cosmo Pharmaceuticals SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オピオイド誘発性便秘治療市場2029：新たな機会を提供する国
• オピオイド誘発性便秘治療市場2029：新たな機会を提供するセグメント
• オピオイド誘発性便秘治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Opioid-induced constipation (OIC) treatment encompasses diverse methods and medications employed to address constipation resulting from opioid use. The objective of these treatments is to relieve constipation symptoms while preserving the pain-relieving benefits of opioids, thus enhancing the patient's quality of life and sustaining effective pain management through a combination of pharmacological and non-pharmacological strategies.

Drug categories for treating opioid-induced constipation comprise laxatives, peripherally acting mu-opioid receptor antagonists, serotonin receptor agonists, and prostaglandins. Laxatives are remedies utilized to stimulate bowel movements and alleviate constipation by enhancing stool frequency and softening stool consistency. They can be administered via various routes, including oral and parenteral routes such as subcutaneous injection, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The opioid-induced constipation market research report is one of a series of new reports from The Business Research Company that provides opioid-induced constipation market statistics, including the opioid-induced constipation industry global market size, regional shares, competitors with opioid-induced constipation market share, detailed opioid-induced constipation market segments, market trends, and opportunities, and any further data you may need to thrive in the opioid-induced constipation industry. These opioid-induced constipation market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.78 billion in 2024 to $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.

The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.

The increasing use of opioids to manage both cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market in the future. Cancer pain refers to the pain associated with cancer and its treatment, while non-cancer pain arises from conditions unrelated to cancer. The administration of opioids for these types of pain is driven by the need to effectively manage moderate to severe pain, taking into account factors such as pain intensity, duration, patient response to other treatments, and the goal of improving quality of life while minimizing the risks of addiction and side effects. OIC treatment helps alleviate constipation caused by opioid use, improving patient comfort, adherence to pain management regimens, and overall quality of life without sacrificing pain relief. For example, according to the Government of Canada, up to 8.3 million Canadians are expected to experience chronic pain by 2025, with this number projected to rise to 9.0 million by 2030. As a result, the growing use of opioids for managing cancer and non-cancer pain is contributing to the expansion of the OIC treatment market.

Leading companies in the opioid-induced constipation (OIC) treatment market are increasingly adopting strategic partnerships to develop innovative medicines. These partnerships enable OIC treatment companies to pool resources and expertise, enhance research and development capabilities, expand their market presence, and accelerate the commercialization of new products, thereby driving innovation and growth in the industry. For example, in November 2022, Kyowa Kirin Co. Ltd., a Japan-based biotechnology company, entered into a partnership with Grunenthal GmbH, a Germany-based pharmaceutical company. This collaboration aims to expand the growth and global availability of a portfolio of transformative pain management medicines, including treatments for opioid-induced constipation, breakthrough cancer pain, and osteoporosis, thereby improving patient outcomes worldwide.

In August 2023, Grunenthal GmbH, a pharmaceutical company headquartered in Germany, finalized a joint venture partnership with Kyowa Kirin International. This collaboration encompasses a collection of 13 brands spanning six therapeutic categories, primarily focusing on pain management, which includes treatments for breakthrough cancer pain, opioid-induced constipation, and osteoporosis. Grunenthal holds a controlling 51% stake in the joint venture, with Kyowa Kirin holding the remaining 49%. Grunenthal aims to acquire the remaining 49% ownership interest at the onset of 2026. Kyowa Kirin International, based in Japan, specializes in developing medications for opioid-induced constipation, including peripherally acting mu-opioid receptor antagonists.

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the opioid-induced constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The opioid-induced constipation treatment market includes revenues earned by entities by providing services such as dietary and lifestyle counselling, medical consultation, diagnostic and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The opioid-induced constipation treatment market also includes sales of injections, tablets, syrups, lubricants, fibre supplements, enemas, suppositories and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opioid-Induced Constipation Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on opioid-induced constipation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for opioid-induced constipation treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opioid-induced constipation treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Laxatives; Peripherally Acting μ-opioid Receptor Antagonists; Serotonin Receptor Agonists; Prostaglandin
• 2) By Type: Oral; Parenteral
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Laxatives: Osmotic Laxatives; Stimulant Laxatives; Bulk-Forming Laxatives
• 2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol; Methylnaltrexone; Alvimopan
• 3) By Serotonin Receptor Agonists: Prucalopride; Tegaserod
• 4) By Prostaglandin: Lubiprostone
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Opioid-Induced Constipation Treatment Market Characteristics

3. Opioid-Induced Constipation Treatment Market Trends And Strategies

4. Opioid-Induced Constipation Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Opioid-Induced Constipation Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Opioid-Induced Constipation Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Opioid-Induced Constipation Treatment Market Growth Rate Analysis
• 5.4. Global Opioid-Induced Constipation Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Opioid-Induced Constipation Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Opioid-Induced Constipation Treatment Total Addressable Market (TAM)

6. Opioid-Induced Constipation Treatment Market Segmentation

• 6.1. Global Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laxatives
• Peripherally Acting Mu-opioid Receptor Antagonists
• Serotonin Receptor Agonists
• Prostaglandin
• 6.2. Global Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Opioid-Induced Constipation Treatment Market, Sub-Segmentation Of Laxatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Osmotic Laxatives
• Stimulant Laxatives
• Bulk-Forming Laxatives
• 6.5. Global Opioid-Induced Constipation Treatment Market, Sub-Segmentation Of Peripherally Acting µ-Opioid Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naloxegol
• Methylnaltrexone
• Alvimopan
• 6.6. Global Opioid-Induced Constipation Treatment Market, Sub-Segmentation Of Serotonin Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prucalopride
• Tegaserod
• 6.7. Global Opioid-Induced Constipation Treatment Market, Sub-Segmentation Of Prostaglandin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lubiprostone

7. Opioid-Induced Constipation Treatment Market Regional And Country Analysis

• 7.1. Global Opioid-Induced Constipation Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Opioid-Induced Constipation Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Opioid-Induced Constipation Treatment Market

• 8.1. Asia-Pacific Opioid-Induced Constipation Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Opioid-Induced Constipation Treatment Market

• 9.1. China Opioid-Induced Constipation Treatment Market Overview
• 9.2. China Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Opioid-Induced Constipation Treatment Market

• 10.1. India Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Opioid-Induced Constipation Treatment Market

• 11.1. Japan Opioid-Induced Constipation Treatment Market Overview
• 11.2. Japan Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Opioid-Induced Constipation Treatment Market

• 12.1. Australia Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Opioid-Induced Constipation Treatment Market

• 13.1. Indonesia Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Opioid-Induced Constipation Treatment Market

• 14.1. South Korea Opioid-Induced Constipation Treatment Market Overview
• 14.2. South Korea Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Opioid-Induced Constipation Treatment Market

• 15.1. Western Europe Opioid-Induced Constipation Treatment Market Overview
• 15.2. Western Europe Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Opioid-Induced Constipation Treatment Market

• 16.1. UK Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Opioid-Induced Constipation Treatment Market

• 17.1. Germany Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Opioid-Induced Constipation Treatment Market

• 18.1. France Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Opioid-Induced Constipation Treatment Market

• 19.1. Italy Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Opioid-Induced Constipation Treatment Market

• 20.1. Spain Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Opioid-Induced Constipation Treatment Market

• 21.1. Eastern Europe Opioid-Induced Constipation Treatment Market Overview
• 21.2. Eastern Europe Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Opioid-Induced Constipation Treatment Market

• 22.1. Russia Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Opioid-Induced Constipation Treatment Market

• 23.1. North America Opioid-Induced Constipation Treatment Market Overview
• 23.2. North America Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Opioid-Induced Constipation Treatment Market

• 24.1. USA Opioid-Induced Constipation Treatment Market Overview
• 24.2. USA Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Opioid-Induced Constipation Treatment Market

• 25.1. Canada Opioid-Induced Constipation Treatment Market Overview
• 25.2. Canada Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Opioid-Induced Constipation Treatment Market

• 26.1. South America Opioid-Induced Constipation Treatment Market Overview
• 26.2. South America Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Opioid-Induced Constipation Treatment Market

• 27.1. Brazil Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Opioid-Induced Constipation Treatment Market

• 28.1. Middle East Opioid-Induced Constipation Treatment Market Overview
• 28.2. Middle East Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Opioid-Induced Constipation Treatment Market

• 29.1. Africa Opioid-Induced Constipation Treatment Market Overview
• 29.2. Africa Opioid-Induced Constipation Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Opioid-Induced Constipation Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Opioid-Induced Constipation Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Opioid-Induced Constipation Treatment Market Competitive Landscape And Company Profiles

• 30.1. Opioid-Induced Constipation Treatment Market Competitive Landscape
• 30.2. Opioid-Induced Constipation Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Opioid-Induced Constipation Treatment Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Daiichi Sankyo Chemical Pharma Co. Ltd.
• 31.3. Bausch Health Companies Inc.
• 31.4. Boehringer Ingelheim International GmbH.
• 31.5. Shionogi & Co. Ltd.
• 31.6. Ono Pharmaceutical Co. Ltd.
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Hikma Pharmaceuticals plc
• 31.9. Mundipharma International Limited
• 31.10. Lantheus Holdings Inc.
• 31.11. Indivior plc
• 31.12. Mallinckrodt Pharmaceuticals
• 31.13. Collegium Pharmaceutical Inc.
• 31.14. Ironwood Pharmaceuticals Inc.
• 31.15. Cosmo Pharmaceuticals SA

32. Global Opioid-Induced Constipation Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Opioid-Induced Constipation Treatment Market

34. Recent Developments In The Opioid-Induced Constipation Treatment Market

35. Opioid-Induced Constipation Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Opioid-Induced Constipation Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Opioid-Induced Constipation Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Opioid-Induced Constipation Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer